Faeth Therapeutics expands board, adds co-founder Karen Vousden
The cancer biologist and Faeth co-founder joins as a sixth director, seated on the Compensation Committee, per a September 17 8-K.
SEC filing
Latest
3 stories
Thursday, September 17
Tuesday, August 4
Faeth Therapeutics reports second-quarter 2026 results, awaits endometrial cancer data
The company said its Phase 2 trial of PIKTOR in endometrial cancer remains on track for year-end topline results, with breast cancer data expected in 2027.
SEC filing
Thursday, July 23
Faeth Therapeutics grants performance stock options to three executives
The board approved one-time performance-based stock options on July 21, 2026, that vest only if Faeth's stock reaches a $70.00 hurdle price.
SEC filing